{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:49:43Z","timestamp":1750942183887,"version":"3.28.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"DOI":"10.7759\/cureus.74268","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T01:36:42Z","timestamp":1732325802000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Epinastine Eyelid Cream in Pediatric Vernal Keratoconjunctivitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Noriyasu","family":"Hashida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Mamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(86)90819-6","article-title":"Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis","volume":"101","author":"BenEzra D","year":"1986","unstructured":"BenEzra D, Pe'er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986, 101:278-82. 10.1016\/0002-9394(86)90819-6","journal-title":"Am J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1350-9462(02)00006-x","article-title":"Vernal keratoconjunctivitis: pathogenesis and treatment","volume":"21","author":"Leonardi A","year":"2002","unstructured":"Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002, 21:319-39. 10.1016\/s1350-9462(02)00006-x","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00699.x","article-title":"Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis","volume":"30","author":"Uchio E","year":"2000","unstructured":"Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy. 2000, 30:103-9. 10.1046\/j.1365-2222.2000.00699.x","journal-title":"Clin Exp Allergy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.586078","article-title":"The role of type 2 innate lymphoid cells in allergic diseases","volume":"12","author":"Zheng H","year":"2021","unstructured":"Zheng H, Zhang Y, Pan J, et al.. The role of type 2 innate lymphoid cells in allergic diseases. Front Immunol. 2021, 12:586078. 10.3389\/fimmu.2021.586078","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-023-08970-4","article-title":"Vernal keratoconjunctivitis: a systematic review","volume":"65","author":"Bruschi G","year":"2023","unstructured":"Bruschi G, Ghiglioni DG, Cozzi L, Osnaghi S, Viola F, Marchisio P. Vernal keratoconjunctivitis: a systematic review. Clin Rev Allergy Immunol. 2023, 65:277-329. 10.1007\/s12016-023-08970-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/children10050808","article-title":"Pediatric conjunctivitis: a review of clinical manifestations, diagnosis, and management","volume":"10","author":"Mahoney MJ","year":"2023","unstructured":"Mahoney MJ, Bekibele R, Notermann SL, Reuter TG, Borman-Shoap EC. Pediatric conjunctivitis: a review of clinical manifestations, diagnosis, and management. Children (Basel). 2023, 10:808. 10.3390\/children10050808","journal-title":"Children (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2017.38.4003","article-title":"Diagnosis and management of allergic conjunctivitis in pediatric patients","volume":"38","author":"Berger WE","year":"2017","unstructured":"Berger WE, Granet DB, Kabat AG. Diagnosis and management of allergic conjunctivitis in pediatric patients. Allergy Asthma Proc. 2017, 38:16-27. 10.2500\/aap.2017.38.4003","journal-title":"Allergy Asthma Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01150-0","article-title":"Allergic conjunctivitis management: update on ophthalmic solutions","volume":"24","author":"Leonardi A","year":"2024","unstructured":"Leonardi A, Quintieri L, Presa IJ, et al.. Allergic conjunctivitis management: update on ophthalmic solutions. Curr Allergy Asthma Rep. 2024, 24:347-60. 10.1007\/s11882-024-01150-0","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2019.1600197","article-title":"Topical tacrolimus for chronic allergic conjunctival disease with and without atopic dermatitis","volume":"44","author":"Shoji J","year":"2019","unstructured":"Shoji J, Ohashi Y, Fukushima A, et al.. Topical tacrolimus for chronic allergic conjunctival disease with and without atopic dermatitis. Curr Eye Res. 2019, 44:796-805. 10.1080\/02713683.2019.1600197","journal-title":"Curr Eye Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/08923979209009219","article-title":"Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition","volume":"14","author":"Kamei C","year":"1992","unstructured":"Kamei C, Akagi M, Mio M, Kitazumi K, Izushi K, Masaki S, Tasaka K. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol. 1992, 14:191-205. 10.3109\/08923979209009219","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/08923979209009220","article-title":"Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects","volume":"14","author":"Kamei C","year":"1992","unstructured":"Kamei C, Mio M, Kitazumi K, Tsujimoto S, Yoshida T, Adachi Y, Tasaka K. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. Immunopharmacol Immunotoxicol. 1992, 14:207-18. 10.3109\/08923979209009220","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2000.36.11.1136048","article-title":"Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases","volume":"36","author":"Tasaka K","year":"2000","unstructured":"Tasaka K. Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today (Barc). 2000, 36:735-57. 10.1358\/dot.2000.36.11.1136048","journal-title":"Drugs Today (Barc)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(04)90003-3","article-title":"Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis","volume":"26","author":"Whitcup SM","year":"2004","unstructured":"Whitcup SM, Bradford R, Lue J, Schiffman RM, Abelson MB. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther. 2004, 26:29-34. 10.1016\/s0149-2918(04)90003-3","journal-title":"Clin Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.iio.0000212128.45395.a5","article-title":"Epinastine in the management of ocular allergic disease","volume":"46","author":"Friedlaender MH","year":"2006","unstructured":"Friedlaender MH. Epinastine in the management of ocular allergic disease. Int Ophthalmol Clin. 2006, 46:85-6. 10.1097\/01.iio.0000212128.45395.a5","journal-title":"Int Ophthalmol Clin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2023.0132","article-title":"Epinastine cream: a novel once-daily therapeutic agent for allergic conjunctivitis","volume":"40","author":"Ogura N","year":"2024","unstructured":"Ogura N, Fujisawa K, Kato M. Epinastine cream: a novel once-daily therapeutic agent for allergic conjunctivitis. J Ocul Pharmacol Ther. 2024, 40:173-80. 10.1089\/jop.2023.0132","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01070-6","article-title":"Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits","volume":"68","author":"Mochizuki T","year":"2024","unstructured":"Mochizuki T, Hata T, Mori N, Yamazaki T, Noto T, Mano H. Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits. Jpn J Ophthalmol. 2024, 68:594-602. 10.1007\/s10384-024-01070-6","journal-title":"Jpn J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01108-9","article-title":"Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial [PREPRINT]","author":"Fujishima H","year":"2024","unstructured":"Fujishima H, Shoji J. Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial [PREPRINT]. Jpn J Ophthalmol. 2024, 10.1007\/s10384-024-01108-9","journal-title":"Jpn J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-6749(98)70023-5","article-title":"Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases","volume":"102","author":"Hingorani M","year":"1998","unstructured":"Hingorani M, Calder V, Jolly G, Buckley RJ, Lightman SL. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J Allergy Clin Immunol. 1998, 102:821-30. 10.1016\/s0091-6749(98)70023-5","journal-title":"J Allergy Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.12.1360","article-title":"Chemokines in the limbal form of vernal keratoconjunctivitis","volume":"84","author":"Abu El-Asrar AM","year":"2000","unstructured":"Abu El-Asrar AM, Struyf S, Al-Kharashi SA, Missotten L, Van Damme J, Geboes K. Chemokines in the limbal form of vernal keratoconjunctivitis. Br J Ophthalmol. 2000, 84:1360-6. 10.1136\/bjo.84.12.1360","journal-title":"Br J Ophthalmol"},{"key":"ref20","article-title":"Modulation of eosinophil survival by epinastine hydrochloride, an H1 receptor antagonist, in vitro","volume":"22","author":"Watase F","year":"2008","unstructured":"Watase F, Watanabe S, Kanai K, et al.. Modulation of eosinophil survival by epinastine hydrochloride, an H1 receptor antagonist, in vitro. In Vivo. 2008, 22:687-91.","journal-title":"In Vivo"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313534-efficacy-of-epinastine-eyelid-cream-in-pediatric-vernal-keratoconjunctivitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T01:36:43Z","timestamp":1732325803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313534-efficacy-of-epinastine-eyelid-cream-in-pediatric-vernal-keratoconjunctivitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.74268","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}